Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DSM265 · 1 trial · 1 indication
The Parasite Reduction Ratio (PRR) is estimated using the slope of the optimal fit of the log-linear relationship of the parasitemia decay.
| Arm | Type | Description |
|---|---|---|
| combination OZ439 and DSM265 | EXPERIMENTAL | Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265. Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics. |
| Name | Type | Description |
|---|---|---|
| DSM265 | DRUG | Single oral doses of DSM265 |
| OZ439 | DRUG | Single oral doses of OZ439 |
Inclusion Criteria: Demography * Adults (male and non-pregnant and non-lactating females) participants between 18 and 55 years of age, inclusive who do not live alone (from Day 0 until at least the end of the antimalarial drug treatment) and be contactable and available for the duration of the tri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
DSM265 is an investigational small molecule being developed for the treatment of malaria. It is currently in Phase 1 clinical development and is being studied as part of a combination therapy for malaria.
DSM265 is being developed for use in malaria. It is currently being studied in a Phase 1 clinical trial for the treatment of malaria, specifically in an induced malaria infection study.
DSM265 is being developed by CNS Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol CNSP.
DSM265 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it remains an investigational drug that has not been approved by regulatory authorities.
DSM265 has been studied in one completed Phase 1 clinical trial, identified as NCT02389348. This trial was an induced malaria infection study that evaluated the combination of OZ439 and DSM265 in healthy volunteers in Australia.
DSM265 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, and its safety and efficacy have not been established for the treatment of malaria.